New Ventures Funds, a venture fund targeting investments in companies across healthcare and life sciences, is pleased to announce the IPO of one of its portfolio companies, Royalty Pharma (NASDAQ:RPRX).
6/25/2020
Royalty Pharma plc today announced the pricing of the initial public offering of 77,681,670 shares of its Class A ordinary shares pursuant to a registration statement on Form S-1 filed with the U.S. Securities and Exchange Commission (“SEC”) at a price to the public of $28.00 per share.
6/15/2020
ADC Therapeutics SA (NYSE:ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates for patients suffering from hematological malignancies and solid tumors, announced today that interim clinical data on loncastuximab tesirine (Lonca, formerly ADCT-402) will be presented in an oral presentation and e-Poster at the virtual 25th Congress of the European Hematology Association (EHA25).
5/21/2020
ADC Therapeutics SA (NYSE: ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates for patients suffering from hematological malignancies and solid tumors, announced today the closing of its initial public offering of 14,082,475 shares of its common shares at a price of $19.00 per ...
5/19/2020
ADC Therapeutics SA, a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates for patients suffering from hematological malignancies and solid tumors, announced today that it has launched the initial public offering of 7,355,000 shares of its common shares. In addition, ADC Therapeutics has granted the underwriters an option to purchase up to 1,103,250 additional common shares. The initial public offering price is expected to be between $16.00 and $18.00 per common share. The common shares have been approved for listing on the New York Stock Exchange under the ticker symbol “ADCT.”
5/11/2020
ADC Therapeutics SA, a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent antibody drug conjugates (ADCs) for patients suffering from hematological malignancies and solid tumors, today announced that it entered into a $115 million Convertible Credit Facility (the “Convertible Credit Facility”) with funds affiliated with Deerfield Management Company, L.P. (collectively, “Deerfield”).
5/1/2020
Enterin, Inc., a clinical-stage company focused on neurodegenerative diseases, announced today that it has received feedback from the FDA laying out the path for a Phase 1/2a study in hospitalized patients with COVID-19 infection. The study will involve 10 U.S. sites and will enroll 80 hospitalized patients. Patients will have been diagnosed with SARS-CoV-2, have an SpO2 ...
4/20/2020
Precision gene-edited traits for one of the world’s largest crops to help reduce farmers’ costs, while improving yield and quality February 13, 2020 08:30 AM Eastern Standard Time SAN DIEGO–(BUSINESS WIRE)–Cibus, a pioneer of precision gene editing in agriculture, today announced significant milestones in developing two new critical traits for rice. In helping provide tolerance to two separate classes of ...
2/13/2020
Dozens of drugmakers are conducting human trials for a record 89 therapies that pair antibodies with toxic agents to fight cancer, evidence of renewed confidence in an approach that has long fallen short of its promise, an analysis compiled for Reuters shows. ...
1/6/2020
FibroGen, Inc. (NASDAQ:FGEN), today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for roxadustat for the treatment of anemia of chronic kidney disease (CKD), in both non-dialysis-dependent (NDD) and dialysis-dependent (DD) CKD patients.
12/23/2019
Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that CAPLYTA® (lumateperone) has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of schizophrenia in adults. The Company expects to initiate the commercial launch of CAPLYTA in late Q1 2020.
12/23/2019
You are here Targeting Alpha-Synuclein in the Gut May Slow Down Parkinson’s Disease 13 November 2019 Scientists are testing the hypothesis that by targeting the gut with a compound that can inhibit the aggregation of alpha-synuclein, they may be able to slow the progression of Parkinson’s disease Amsterdam, NL – Aggregates of the protein alpha-synuclein arising in the gut may ...
11/18/2019
Cibus, a pioneer of precision gene editing for agriculture, has reached significant milestones in developing three new traits for canola, which can increase crop yields for farmers and reduce harmful environmental impacts.
11/6/2019
N. Harris Computer Corporation’s (“Harris”) healthcare group announced today that it has completed the acquisition of Connecture, Inc. (“Connecture”).…
10/7/2019
ADC Therapeutics SA, a clinical-stage oncology-focused biotechnology company pioneering the development of highly potent and targeted antibody drug conjugates for patients suffering from hematological malignancies and solid tumors, announced today that it has filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission relating to a proposed initial public ...
9/6/2019
A new approach to beating herpes by inducing antibodies that mediate the killing of infected cells -Participants include Johnson & Johnson Innovation – JJDC, Inc. (JJDC); Adjuvant Capital, an impact investment fund supported by the Bill & Melinda Gates Foundation as an anchor investor; Serum Institute of India; Alexandria Venture Investments; Founders Fund. X-Vax Technology NEWS PROVIDED BY X-Vax Technology, ...
7/23/2019
FibroGen, Inc. (NASDAQ: FGEN), today announced that the company will present interim data on their open-label, single-arm…
6/28/2019
FibroGen, Inc. (NASDAQ: FGEN), a leading biopharmaceutical company discovering and developing a pipeline of first-in-class therapeutics, today…
6/10/2019
Positive topline results from pooled safety analyses of roxadustat Phase 3 global program Completed one year of treatment in Phase 2 trial evaluating pamrevlumab in…
5/9/2019
MACE/MACE+ endpoints evaluated across CKD patients not on dialysis and on dialysis Superiority in time to first MACE+ versus epoetin alfa in incident dialysis patients…
5/9/2019
